Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gecacitinib + ATG for aGVHD Prophylaxis in Myelofibrosis After Allo-HSCT
NCT07440654Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Mar 2026
- Primary completion
- Sep 2029
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of jaktinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Incidence of grade 3-4 acute Graft-Versus-Host Disease at 14 weeks. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
jaktinib
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT07440654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07440654.